{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T06:41:36Z","timestamp":1778568096165,"version":"3.51.4"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Environmental Toxicology and Pharmacology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.etap.2022.103979","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T13:39:27Z","timestamp":1664199567000},"page":"103979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Sublingual buprenorphine\/naloxone treatment is not affected by OPRM1 A118G and BDNF Va66Met polymorphisms, but alters the plasma beta-endorphin and BDNF levels in individuals with opioid use disorder"],"prefix":"10.1016","volume":"95","author":[{"given":"Dilek","family":"Kaya-Aky\u00fczl\u00fc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selin","family":"\u00d6zkan-Kotilo\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ceylan","family":"Bal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gamze","family":"Avc\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eafak","family":"Yal\u00e7\u0131n-\u015eahiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130smail Volkan","family":"\u015eahiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.etap.2022.103979_bib1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1186\/s13063-018-3055-z","article-title":"Single high-dose buprenorphine for opioid craving during withdrawal","volume":"19","author":"Ahmadi","year":"2018","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.etap.2022.103979_bib2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s12031-018-1123-1","article-title":"Implication of OPRM1 A118G polymorphism in opioids addicts in Pakistan: in vitro and in silico analysis","volume":"65","author":"Ahmed","year":"2018","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.etap.2022.103979_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fpsyt.2020.00469","article-title":"BDNF mRNA expression in leukocytes and frontal cortex function in drug use disorder","volume":"11","author":"Anders","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.etap.2022.103979_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13722-015-0040-7","article-title":"Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study","volume":"10","author":"Bawor","year":"2015","journal-title":"Addict. Sci. Clin. Pr."},{"key":"10.1016\/j.etap.2022.103979_bib5","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1074\/jbc.M006352200","article-title":"A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling","volume":"0","author":"Befort","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.etap.2022.103979_bib6","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1471-4159.2004.02340.x","article-title":"Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor","volume":"89","author":"Beyer","year":"2004","journal-title":"J. Neurochem"},{"key":"10.1016\/j.etap.2022.103979_bib7","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1073\/pnas.95.16.9608","article-title":"Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction","volume":"95","author":"Bond","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.etap.2022.103979_bib8","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1007\/s11606-020-06115-3","article-title":"Treating perioperative and acute pain in patients on buprenorphine: narrative literature review and practice recommendations","volume":"35","author":"Buresh","year":"2020","journal-title":"J. Gen. Intern Med."},{"key":"10.1016\/j.etap.2022.103979_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000336997","article-title":"Increase in serum brain-derived neurotrophic factor in met allele carriers of the BDNF Val66Met polymorphism is specific to males","volume":"65","author":"Bus","year":"2012","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.etap.2022.103979_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5455\/bcp.20150404070711","article-title":"Reliability and validity of the turkish version of the clinical opiate withdrawal scale (COWS)","volume":"25","author":"Canan","year":"2015","journal-title":"Bull. Clin. Psychopharmacol."},{"key":"10.1016\/j.etap.2022.103979_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0376-8716(98)00192-6","article-title":"Plasma concentrations of buprenorphine 24 to 72\u2009h after dosing","volume":"55","author":"Chawarski","year":"1999","journal-title":"Drug Alcohol. Depend."},{"key":"10.1016\/j.etap.2022.103979_bib12","doi-asserted-by":"crossref","first-page":"8148","DOI":"10.1038\/srep08148","article-title":"The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese heroin-dependent patients","volume":"5","author":"Chen","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.etap.2022.103979_bib13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.21037\/atm.2019.08.53","article-title":"Increased risk of intracranial hemorrhage in preterm infants with OPRM1 gene A118G polymorphism","volume":"7","author":"Cheng","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.etap.2022.103979_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000457","article-title":"Buprenorphine pharmacology review: update on transmucosal and long-acting formulations","volume":"13","author":"Coe","year":"2019","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.etap.2022.103979_bib15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/00952990.2017.1420795","article-title":"Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate","volume":"44","author":"Crist","year":"2018","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"10.1016\/j.etap.2022.103979_bib16","first-page":"674","article-title":"Pharmacogenomics and opioid use disorder: clinical decision support in an African American Cohort","volume":"111","author":"Ettienne","year":"2019","journal-title":"J. Natl. Med. Assoc."},{"key":"10.1016\/j.etap.2022.103979_bib17","first-page":"70","article-title":"Reliability and validity of the Penn Alcohol Craving Scale (PACS) Revised Version for substance craving in male substance dependent inpatients","volume":"22","author":"Evren","year":"2011","journal-title":"Turk. J. Psychiatry"},{"key":"10.1016\/j.etap.2022.103979_bib18","unstructured":"U.S. Food and Drug Administation, 2002. Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020733s007s008lbl.pdf. (accessed 15 December 2021)."},{"key":"10.1016\/j.etap.2022.103979_bib19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0006-8993(83)90113-0","article-title":"Autoradiography of [3H]L-endorphin binding in brain","volume":"288","author":"Goodman","year":"1983","journal-title":"Brain Res."},{"key":"10.1016\/j.etap.2022.103979_bib20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/nn1929","article-title":"Dynamic BDNF activity in nucleus accumbens with cocaine use increases self-administration and relapse","volume":"10","author":"Graham","year":"2007","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.etap.2022.103979_bib21","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1369-1600.2011.00431.x","article-title":"BDNF Val(66)Met genotype is associated with drug-seeking phenotypes in heroin-dependent individuals: a pilot study","volume":"18","author":"Greenwald","year":"2013","journal-title":"Addict. Biol."},{"key":"10.1016\/j.etap.2022.103979_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.comppsych.2015.06.008","article-title":"Serum brain-derived neurotrophic factor levels and psychotic symptoms in heroin dependence","volume":"62","author":"Han","year":"2015","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.etap.2022.103979_bib23","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/0269881111411332","article-title":"Serum levels of BDNF are associated with craving in opiate-dependent patients","volume":"25","author":"Heberlein","year":"2011","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.etap.2022.103979_bib24","first-page":"357","article-title":"Is serum brain-derived neurotrophic factor related to craving for or use of alcohol, cocaine, or methamphetamine?","volume":"7","author":"Hilburn","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.etap.2022.103979_bib25","doi-asserted-by":"crossref","first-page":"e755","DOI":"10.1542\/peds.2006-0223","article-title":"Age of alcohol-dependence onset: associations with severity of dependence and seeking treatment","volume":"118","author":"Hingson","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.etap.2022.103979_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03639045.2019.1706552","article-title":"Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy data","volume":"46","author":"Hjelmstr\u00f6m","year":"2020","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.etap.2022.103979_bib27","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1523\/JNEUROSCI.04-10-02460.1984","article-title":"[3H]-L-Endorphin binding in rat brain","volume":"4","author":"Houghten","year":"1984","journal-title":"J. Neurosci."},{"key":"10.1016\/j.etap.2022.103979_bib28","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/350230a0","article-title":"BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra","volume":"350","author":"Hyman","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.etap.2022.103979_bib29","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1213\/01.ane.0000231634.20341.88","article-title":"A genetic association study of the functional A118G polymorphism of the human Mu-opioid receptor gene in patients with acute and chronic pain","volume":"103","author":"Janicki","year":"2006","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.etap.2022.103979_bib30","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","article-title":"A controlled trial of buprenorphine treatment for opioid dependence","volume":"267","author":"Johnson","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.etap.2022.103979_bib31","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neulet.2005.06.042","article-title":"High concentrations of plasma brain-derived neurotrophic factor in methamphetamine users","volume":"388","author":"Kim","year":"2005","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.etap.2022.103979_bib32","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1111\/bph.12785","article-title":"Buprenorphine signalling is compromised at the N40D polymorphism of the human \u03bc opioid receptor in vitro","volume":"171","author":"Knapman","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.etap.2022.103979_bib33","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0006-3223(92)90220-T","article-title":"Beta endorphin levels during heroin, methadone, buprenorphine, and naloxone challenges: preliminary findings","volume":"32","author":"Kosten","year":"1992","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.etap.2022.103979_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ijnp\/pyaa069","article-title":"A delta-opioid receptor gene polymorphism moderates the therapeutic response to extended-release buprenorphine in opioid use disorder","volume":"24","author":"Kranzler","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.etap.2022.103979_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1471-4159.2007.04738.x","article-title":"The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor","volume":"103","author":"Kroslak","year":"2007","journal-title":"J. Neurochem"},{"key":"10.1016\/j.etap.2022.103979_bib36","unstructured":"Kumar, R., Viswanath, O., Saadabadi, A. 2021. Buprenorphine. [Updated 2021 Aug 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459126\/."},{"key":"10.1016\/j.etap.2022.103979_bib37","doi-asserted-by":"crossref","first-page":"A32","DOI":"10.1055\/s-0033-1353293","article-title":"Therapeutic drug-monitoring for opiate-dependent patients receiving buprenorphine for substitution","volume":"46","author":"Laib","year":"2013","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.etap.2022.103979_bib38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/mp.2008.80","article-title":"The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations","volume":"14","author":"Lang","year":"2009","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.etap.2022.103979_bib39","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0028-3908(87)90112-2","article-title":"Buprenorphine has potent kappa opioid receptor antagonist activity","volume":"26","author":"Leander","year":"1987","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.etap.2022.103979_bib40","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/00000542-200210000-00011","article-title":"Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?","volume":"97","author":"L\u00f6tsch","year":"2002","journal-title":"Anesthesiology"},{"key":"10.1016\/j.etap.2022.103979_bib41","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1523\/JNEUROSCI.5124-03.2004","article-title":"A single infusion of brain-derived neurotrophic factor into the ventral tegmental area induces long-lasting potentiation of cocaine seeking after withdrawal","volume":"24","author":"Lu","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.etap.2022.103979_bib42","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1017\/S0033291720000525","article-title":"Buprenorphine: prospective novel therapy for depression and PTSD","volume":"50","author":"Madison","year":"2020","journal-title":"Psychol. Med."},{"key":"10.1016\/j.etap.2022.103979_bib43","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-3565(25)30536-7","article-title":"The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog","volume":"197","author":"Martin","year":"1976","journal-title":"Pharmacol. Exp. Ther."},{"key":"10.1016\/j.etap.2022.103979_bib44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00406-011-0189-3","article-title":"BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects","volume":"261","author":"Minelli","year":"2011","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.etap.2022.103979_bib45","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0306-4522(02)00486-4","article-title":"Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons\/medulla of the mu-opioid receptor knockout mouse","volume":"115","author":"Mizoguchi","year":"2002","journal-title":"Neuroscience"},{"key":"10.1016\/j.etap.2022.103979_bib46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00008877-200211000-00005","article-title":"Delta opioid antagonist efects of buprenorphine in rhesus monkeys","volume":"13","author":"Negus","year":"2002","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.etap.2022.103979_bib47","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0022-3565(25)12708-0","article-title":"Affinity of drugs and peptides for U-69, 593-sensitive and -insensitive kappa opiate binding sites: the U-69, 593-insensitive site appears to be the beta-endorphin-specific epsilon receptor","volume":"254","author":"Nock","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.etap.2022.103979_bib48","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0022-3565(25)10275-9","article-title":"Properties of the putative epsilon opioid receptor: identication in rat, guinea pig, cow, pig and chicken brain","volume":"264","author":"Nock","year":"1993","journal-title":"J. Pharmacol. Exp. . R."},{"key":"10.1016\/j.etap.2022.103979_bib49","series-title":"The Pharmacology of Opioid Peptides","first-page":"29","article-title":"Kappa and epsilon receptor binding","author":"Nock","year":"1995"},{"key":"10.1016\/j.etap.2022.103979_bib50","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/ijms22010338","article-title":"Roles of \u03b2-endorphin in stress, behavior, neuroinflammation, and brain energy metabolism","volume":"22","author":"Pilozzi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.etap.2022.103979_bib51","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1134\/S0006297917030099","article-title":"Neurotrophic Factors (BDNF and GDNF) and the serotonergic system of the brain","volume":"82","author":"Popova","year":"2017","journal-title":"Biochem. (Mosc. )"},{"key":"10.1016\/j.etap.2022.103979_bib52","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12888-016-1191-0","article-title":"Age of onset of substance use and psychosocial problems among individuals with substance use disorders","volume":"17","author":"Poudel","year":"2017","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.etap.2022.103979_bib53","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/00952990.2020.1797064","article-title":"Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians","volume":"46","author":"Randesi","year":"2020","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"10.1016\/j.etap.2022.103979_bib54","doi-asserted-by":"crossref","first-page":"9268","DOI":"10.1073\/pnas.1018699108","article-title":"Human Mu opioid receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers","volume":"108","author":"Ray","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.etap.2022.103979_bib55","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000492582","article-title":"Increased risk-taking behaviour and brain-derived neurotrophic factor Val66Met polymorphism correlates to decreased serum brain-derived neurotrophic factor level in heroin users","volume":"24","author":"Rovi\u0161","year":"2018","journal-title":"Eur. Addict. Res."},{"key":"10.1016\/j.etap.2022.103979_bib56","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.3390\/pharmaceutics12121226","article-title":"Pharmacokinetic characterization and external evaluation of a quantitative framework of sublingual buprenorphine in patients with an opioid disorder in puerto rico","volume":"12","author":"Santiago","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.etap.2022.103979_bib57","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000097349","article-title":"Molecular biology of opioid receptors","volume":"4","author":"Singh","year":"1997","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.etap.2022.103979_bib58","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pharep.2017.08.002","article-title":"Val66Met functional polymorphism and serum protein level of brain-derived neurotrophic factor (BDNF) in acute episode of schizophrenia and depression","volume":"70","author":"Skibinska","year":"2018","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.etap.2022.103979_bib59","first-page":"361","article-title":"OPRM1 A118G polymorphisms and its role in opioid addiction: implication on severity and treatment approaches","volume":"12","author":"Taqi","year":"2019","journal-title":"Pharmgenom. Pers. Med"},{"key":"10.1016\/j.etap.2022.103979_bib60","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.psychres.2016.12.042","article-title":"Brain-derived neurotrophic factor (BDNF) and oxidative stress in heroin-dependent male patients undergoing methadone maintenance treatment","volume":"249","author":"Tsai","year":"2017","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.etap.2022.103979_bib61","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1126\/science.1168501","article-title":"Ventral tegmental area BDNF induces an opiate-dependent-like reward state in naive rats","volume":"324","author":"Vargas-Perez","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.etap.2022.103979_bib62","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/0963689718811060","article-title":"Historical review: opiate addiction and opioid receptors","volume":"28","author":"Wang","year":"2019","journal-title":"Cell Transpl."},{"key":"10.1016\/j.etap.2022.103979_bib63","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1017\/S146114571200017X","article-title":"Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects","volume":"16","author":"Weerts","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.etap.2022.103979_bib64","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/ajad.12187","article-title":"Functional mu opioid receptor polymorphism (OPRM1 A(118) G) associated with heroin use outcomes in Caucasian males: a pilot study","volume":"24","author":"Woodcock","year":"2015","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.etap.2022.103979_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111515","article-title":"Alterations in neurotransmitter levels and transcription factor expression following intranasal buprenorphine administration","volume":"138","author":"Xhakaza","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.etap.2022.103979_bib66","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.pnpbp.2011.02.009","article-title":"The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients","volume":"35","author":"Yoshimura","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.etap.2022.103979_bib67","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1460-9568.2006.04621.x","article-title":"Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through delta- and micro-opioid receptors independent of antidepressant-like effects","volume":"23","author":"Zhang","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.etap.2022.103979_bib68","doi-asserted-by":"crossref","first-page":"32618","DOI":"10.1074\/jbc.M504942200","article-title":"Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G","volume":"280","author":"Zhang","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.etap.2022.103979_bib69","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1515\/CCLM.2011.039","article-title":"Decreased serum brain-derived neurotrophic factor (BDNF) is associated with post-stroke depression but not with BDNF gene Val66Met polymorphism","volume":"49","author":"Zhou","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.etap.2022.103979_bib70","first-page":"313","article-title":"Buprenorphine therapy for opioid use disorder","volume":"97","author":"Zoorob","year":"2018","journal-title":"Am. Fam. Physician"}],"container-title":["Environmental Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1382668922001727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1382668922001727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T09:51:24Z","timestamp":1761299484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1382668922001727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":70,"alternative-id":["S1382668922001727"],"URL":"https:\/\/doi.org\/10.1016\/j.etap.2022.103979","relation":{},"ISSN":["1382-6689"],"issn-type":[{"value":"1382-6689","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sublingual buprenorphine\/naloxone treatment is not affected by OPRM1 A118G and BDNF Va66Met polymorphisms, but alters the plasma beta-endorphin and BDNF levels in individuals with opioid use disorder","name":"articletitle","label":"Article Title"},{"value":"Environmental Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.etap.2022.103979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103979"}}